Investigational
Retatrutide
Retatrutide is a single synthetic peptide, developed by Eli Lilly as LY3437943, that activates the GIP, GLP-1, and glucagon receptors. It is not an approved medicine.
Research summary only. Not medical advice, not a protocol, and not for human or veterinary consumption.
- Also called
- LY3437943
- CAS
- 2381089-83-2
- Formula
- C221H342N46O68
- Evidence
- Investigational
Mechanism
It is a unimolecular triple agonist. Adding glucagon-receptor activity to GIP and GLP-1 activity was explored first with designed tri-agonists in preclinical work, then taken into clinical trials as this peptide. Receptor occupancy in a dish is not evidence that a research vial behaves like a trial injection.
Evidence
A phase 2 obesity trial was published in the New England Journal of Medicine in 2023. Through 2026 the sponsor reported further positive phase 3 topline results from the TRIUMPH program, including a 23 July 2026 announcement on TRIUMPH-2 and TRIUMPH-3, and discussed a US submission aimed at the first quarter of 2027. Topline company announcements are not peer-reviewed papers and they are not a licence. As of those announcements, retatrutide was still unapproved.
Limitations
This catalogue material is not clinical-trial supply and not a future licensed product. Salt form, purity, and exact sequence belong on the batch record; published formulae can differ from a weighed salt. We do not quote trial doses, and we do not treat weight-loss percentages as a property of a research vial. Gastrointestinal effects were prominent in the trial reports. Not for human or veterinary use.
